Serial 'deep-sampling' PCR of fragmented DNA reveals the wide range of <i>Trypanosoma cruzi</i> burden among chronically infected human, macaque, and canine hosts, and allows accurate monitoring of parasite load following treatment.

Abstract

Infection with the protozoan parasite <i>Trypanosoma cruzi</i> is generally well-controlled by host immune responses, but appears to be rarely eliminated. The resulting persistent, low-level infection results in cumulative tissue damage with the greatest impact generally in the heart in the form of chagasic cardiomyopathy. The relative success in immune control of <i>T. cruzi</i> infection usually averts acute phase death but has the negative consequence that the low-level presence of <i>T. cruzi</i> in hosts is challenging to detect unequivocally. Thus, it is difficult to identify those who are actively infected and, as well, problematic to gauge the impact of treatment, particularly in the evaluation of the relative efficacy of new drugs. In this study, we employ DNA fragmentation and high numbers of replicate PCR reaction ('deep-sampling') and to extend the quantitative range of detecting <i>T. cruzi</i> in blood by at least three orders of magnitude relative to current protocols. When combined with sampling blood at multiple time points, deep sampling of fragmented DNA allowed for detection of <i>T. cruzi</i> in all infected hosts in multiple host species, including humans, macaques, and dogs. In addition, we provide evidence for a number of characteristics not previously rigorously quantified in the population of hosts with naturally acquired <i>T. cruzi</i> infection, including, a >6 log variation between chronically infected individuals in the stable parasite levels, a continuing decline in parasite load during the second and third years of infection in some hosts, and the potential for parasite load to change dramatically when health conditions change. Although requiring strict adherence to contamination-prevention protocols and significant resources, deep-sampling PCR provides an important new tool for assessing therapies and for addressing long-standing questions in <i>T. cruzi</i> infection and Chagas disease.